Navigation Links
Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic
Date:6/16/2008

HAE:TSX

MONTREAL, June 16 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announces that it has raised $7.8 million through the exercise of amended Series B warrants and broker warrants issued as part of the private placement concluded in January 2007.

"I sincerely thank our shareholders who demonstrated their strong support by exercising their warrants. We now have the financial resources to execute on all of the necessary milestones to get our fibrin sealant into the clinic in Q1-09. This financing significantly reduces the financial risk. All of our time and attention will be focused on execution and getting a green light from the FDA to enter clinical trials." said Joseph Galli, Chairman and CEO of Haemacure.

Manufacturing Facility

On June 4th, Haemacure began fractionating plasma in its new facility in Sarasota, Florida. It is on-schedule and on-budget to produce fibrin sealant clinical lots during Q3-08 and to file an amendment to its existing IND with the U.S. FDA during Q4-08.

Haemacure's fractionation facility is the first and only U.S.-based manufacturing facility for fibrin sealant destined for the U.S. market and this is of significant strategic value.

Fibrin Sealant Pivotal Clinical Trials

The safety of Haemacure's lead product candidate, all-human fibrin sealant, was demonstrated in past clinical trials as no serious adverse events related to the product were reported. The efficacy of the product was also significantly superior to the standard of care used in the control group.

New Preclinical Study in Adhesion Prevention

Encouraged by the positive results of the preclinical study Haemacure conducted on the efficacy of its all-human fibrin sealant in preventing the formation of post-surgical adhesions, Haemacure will sponsor a second study for the same application, in a slightly different model.

Market Opportunities

Haemacure is currently pursuing business development opportunities in six market segments where fibrin sealant has application, beyond its core haemostasis segment. These are wound management, adhesion prevention, regenerative medicine, drug delivery, in combination with biomaterials, and cosmetics. All these segments represent major growth opportunities that Haemacure will leverage.

Haemacure is pursuing strategic partnerships for the development of the proteins it has identified in one of its two plasma fractions: albumin, alpha-1 anti-trypsyn, immunoglobulin and plasminogen.

About Haemacure

Haemacure Corporation is a specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medicine, drug delivery and combinations with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one of its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates a manufacturing facility in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.


'/>"/>
SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
2. Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
3. Haemacure Reports on Financing Progress and Second Quarter Results
4. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
5. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Haemacure financing receives shareholder consent - Series B Warrants are amended
7. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
8. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
9. Haemacure Reports on its annual general and special meeting of shareholders
10. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
11. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... In his newly appointed role ... May, Ph.D., recently accepted the distinguished Sun Corridor Export Award for his company’s ... (WNB), and 16 other businesses from Pima, Pinal, and Maricopa counties in Arizona, ...
(Date:6/20/2017)... West Hempstead, NY (PRWEB) , ... June 20, ... ... most experienced in the security systems industry has been selected as the partner ... , Amtrak is a passenger railroad service that provides medium- and long-distance intercity ...
(Date:6/20/2017)... ... 2017 , ... John D'Eri, CEO of Rising Tide Car Wash , ... during the Autism Society of America 's 49th annual conference to be ... Foundation (DJFF) was founded in 2002 as the nation's first autism organization focused ...
(Date:6/20/2017)... ... June 20, 2017 , ... MEDI+SIGN, ... like to officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN Advisory Board. ... and expertise in healthcare will provide invaluable direction for the company,” says Andrew ...
(Date:6/20/2017)... ... , ... The law firm of Momkus McCluskey Roberts LLC congratulates ... DuPage County Bar Association’s Board of Directors. Cassioppi officially took on the leadership role ... Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also installed as ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
Breaking Medicine Technology: